-
E-mail
inquire-china_lsca@agilent.com
- Phone
-
Address
No. 3 Wangjing North Road, Chaoyang District, Beijing
Agilent Technologies (China) Co., Ltd
inquire-china_lsca@agilent.com
No. 3 Wangjing North Road, Chaoyang District, Beijing

The 'aha moment' in scientific research is sometimes hidden in a casual inspection of discarded samples.
Dr. Jiang Shengwei from Sun Yat sen Medical College, Sun Yat sen University, tested the sample that should have been discarded with a terminal reagent after completing the organoid drug screening experiment, and unexpectedly found that it could secrete insulin. This phenomenon has triggered a series of questions: Will a micro tissue cultured in vitro affect systemic metabolism? The team subsequently validated in db/db mice and found that after a single subcutaneous implantation, blood glucose levels steadily decreased for up to a month.
Oh, isn't that right? "Many people have had similar thoughts. But Dr. Jiang and his team chose to ask: If it can secrete insulin, will it affect systemic metabolism? So, they designed a complete set of validation experiments by subcutaneously implanting organoids into db/db mice, and then using multiple omics methods such as metabolomics, proteomics, and single-cell sequencing to systematically observe the response of the liver, fat, and muscle tissues.
In this issue of 'Science Speaks', we invite Dr. Jiang Shengwei to reminisce and document the complete research path from' What? 'to' Aha! 'together. There is no predetermined answer, only respect for abnormal data, adherence to verification logic, and honest sharing of how technical tools support discovery.
Agilent's cell analysis technology and other platforms actively participated in Dr. Jiang's discovery and exploration process, providing key support for the precise quantification of metabolites and proteins. It is precisely these technological tools that help them move from "abnormal phenomena" to a preliminary understanding of the mechanism: organoids may not directly lower blood sugar, but activate the metabolic function of the host's own organs through the secretion of factors - like tiny "regulators".
This study also reflects the scientific positioning of organoid technology: it is neither a universal solution to replace animal models nor an isolated cell cluster, but an intermediate model that can be manipulated, validated, and integrated with other technologies such as organ chips and 3D bioprinting. The premise for constructing it precisely comes from Dr. Jiang's daily lectures on human anatomy - only by understanding the spatial relationships and connection logic between organs can cross organ communication be reasonably simulated in vitro.

Jiang Shengwei, Associate Professor and Master's Supervisor in the Department of Human Anatomy. Graduated from Central South University in 2014 with a Bachelor's degree in Medicine. I graduated from the School of Public Health, Xiamen University in 2017 with a Master's degree in Translational Medicine. I graduated from Tsinghua University, Tsinghua Berkeley Shenzhen College in 2021 with a major in Precision Medicine and Public Health, and obtained a Doctor of Medicine degree. I will conduct postdoctoral research at Shenzhen University General Hospital from 2021 to 2023. Introduced to work in October 2023 and selected for the "Yixian Scholar" program.